Results 51 to 60 of about 284,082 (261)

Angiotensin-Converting Enzyme Inhibitor Protects Against Cisplatin Nephrotoxicity by Modulating Kinin B1 Receptor Expression and Aminopeptidase P Activity in Mice

Frontiers in Molecular Biosciences, 2020
Cisplatin is a highly effective chemotherapeutic agent. However, its use is limited by nephrotoxicity. Enalapril is an angiotensin I-converting enzyme inhibitor used for the treatment of hypertension, mainly through the reduction of angiotensin II ...
Gabriel R. Estrela, Gabriel R. Estrela, Frederick Wasinski, Marcos F. Gregnani, Leandro C. Freitas-Lima, Adriano C. Arruda, Rafael Leite Morais, Denise MAC Malheiros, Niels O. S. Camara, João Bosco Pesquero, Michael Bader, Michael Bader, Michael Bader, Michael Bader, Carlos Castilho Barros, Ronaldo Carvalho Araújo, Ronaldo Carvalho Araújo   +16 more
doaj   +1 more source

p190A/ARHGAP35 and p190B/ARHGAP5 proteins in endometrial cancer: a novel cancer‐relevant paralog interplay

Molecular Oncology, EarlyView.
This study identifies ARHGAP5, in addition to the frequently mutated ARHGAP35, as significantly mutated in endometrial cancer. Mutations in both genes co‐occur and are associated with their correlated downregulation. Functional CRISPR studies show that both paralogs regulate similar pathways, including actin cytoskeleton organization.
Mathilde Pinault, Capucine Heraud, Mélissa Correia de Oliveira, Véronique Neaud, Valérie Valesco, Valérie Prouzet‐Mauleon, Béatrice Turcq, Jean‐William Dupuy, Anne‐Aurélie Raymond, Sabrina Croce, Frédéric Saltel, Valérie Lagrée, Violaine Moreau   +12 more
wiley   +1 more source

SPHINX31 acts as a SRPK1 inhibitor targeting the ATR/DNA‐PKcs/CHK1 replicative checkpoint to inhibit cell growth in non‐small cell lung cancer

Molecular Oncology, EarlyView.
The kinase SRPK1 directly interacts with the protein TOPBP1 and regulates the pre‐mRNA splicing of WIZ thereby contributing to the activation of the ATR/CHK1 replicative checkpoint in response to replicative stress. This allows cancer cells' genomic stability and survival.
Amani Shreim, Aurelie Genoux, Nadiia Zubchuk, Haoyang Zheng, Perla Salameh, Theo Ziegelmeyer, Fabien Dalonneau, Margot Rouchette, Christiane Oddou, Simona Miron, Helene Polveche, Adiilah Mamode Cassim, Carmen Garrido, Eleni Nikolakaki, Didier Auboeuf, Tao Jia, Sophie Zinn‐Justin, Beatrice Eymin   +17 more
wiley   +1 more source

Quantification of Cisplatin Encapsulated in Nanomedicine: An Overview

Biosensors
Cisplatin, which kills cancer cells mainly through DNA crosslinking, has been widely used as a first-line chemotherapeutic agent although it also causes severe side effects.
Ziwen Zhang, Jiayu Chen, Tao Wen, Hong Deng, Yiyi Zhang, Hua Guo, Hui Chang, Haiyan Xu, Weiqi Zhang   +8 more
doaj   +1 more source

New combination chemotherapy of cisplatin with an electron-donating compound for treatment of multiple cancers

Scientific Reports, 2021
Cisplatin is the first and most widely used platinum-based chemotherapy drug and is the cornerstone agent in treating a broad spectrum of cancers. However, its clinical application is often limited by severe toxic side effects and drug resistance.
Qinrong Zhang, Qing-Bin Lu
doaj   +1 more source

UiO‐66 metal–organic frameworks in biomedicine: From structural tunability to bioimaging, photodiagnostics, and photodynamic cancer therapy

FEBS Open Bio, EarlyView.
UiO‐66(Zr) metal–organic frameworks are chemically stable, biocompatible, and highly tunable nanomaterials. Their modular structure enables controlled drug delivery, multimodal bioimaging, and light‐activated photodynamic therapy, supporting integrated diagnostic and therapeutic (theranostic) applications in cancer and biomedical research.
Veronika Huntošová, Grigorii Rakhalskii, Miroslav Almáši   +2 more
wiley   +1 more source

New precious metal compounds in cancer therapy [PDF]

, 2008
Includes abstract.Includes bibliographical references (leaves 139-160).Cisplatin is one of the most effective cancer medications currently available. However, it is seriously limited by patient toxicity and drug resistance.
Peters, Dean Douglas
core   +1 more source

Synthesis of Self-Assembled Nanostructured Cisplatin Using the RESS Process

Pharmaceutics
Background/Objectives: The primary goal of our research is to develop a process to prepare an aqueous dispersion of Cisplatin, an important anticancer drug, with increased solubility and storage stability.
Sudhir Kumar Sharma, Loganathan Palanikumar, Renu Pasricha, Thirumurugan Prakasam, Mazin Magzoub, Ramesh Jagannathan   +5 more
doaj   +1 more source

Activation of the cholinergic anti-inflammatory pathway by GTS-21 attenuates cisplatin-induced acute kidney injury in mice. [PDF]

PLoS ONE, 2017
Acute kidney injury (AKI) is the most common side effect of cisplatin, a widely used chemotherapy drug. Although AKI occurs in up to one third of cancer patients receiving cisplatin, effective renal protective strategies are lacking.
Prodyot K Chatterjee, Michael M Yeboah, Malvika H Solanki, Gopal Kumar, Xiangying Xue, Valentin A Pavlov, Yousef Al-Abed, Christine N Metz   +7 more
doaj   +1 more source

Loss of AMBRA1 activates MAPK and angiogenesis signaling pathways in melanoma cells

FEBS Open Bio, EarlyView.
Loss of AMBRA1 in melanoma cells activates multiple oncogenic pathways associated with tumor progression. Transcriptomic and protein network analyses revealed that AMBRA1 depletion enhances MAPK/ERK signaling, angiogenesis, TGF‐β/EMT signaling, and Wnt/axon guidance pathways.
Milad Ibrahim, Marco Corazzari, Iman Osman, Jane Armstrong, Noel Carter   +4 more
wiley   +1 more source